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Background: We report the long-term outcomes of patients with osteosarcoma who underwent effective preoperative
chemotherapy and subsequently underwent marginal resection.
Methods: We reviewed the records of 50 patients with osteosarcoma who underwent marginal resection following
effective preoperative chemotherapy; 18 were treated with the MMIA (high-dose methotrexate (HD-MTX), adriamycin
(ADR), ifosfamide (IFO)) and cisplatin (DDP), and 32 patients were treated with the DIA (DDP, ADR and IFO). protocol. The
functions of the affected limb were evaluated using the revised MSTS93 system. The Kaplan-Meier method was used for
survival analysis.
Results: After a median follow-up of 5.5 years, the rates were: overall 5-year cumulative survival 61.7%, event-free survival
57.7%, recurrence 8.5%, pulmonary metastases 42.6%, and excellent to good function of the affected limb 57.7%.
Conclusions: Our results showed that marginal resection can be performed in patients with osteosarcoma who obtain
clinically favorable responses to chemotherapy. Patients had a good clinical course and there was no negative effect on
rates of survival or local recurrence.
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Neoadjuvant chemotherapy and limb preservation is
standard treatment for osteosarcoma of the extremities.
The classic surgical goal is to create wide surgical mar-
gins, but greater excision of structures leads to poorer
function. Recently, the need for wide surgical margins
has been questioned, with the aim of preserving limb
function. Surgical resection should be minimized when-
ever possible without increasing the risk of local recur-
rence or jeopardizing the patient’s life. This is the ideal
therapeutic strategy for preserving the quality of life of
patients with osteosarcoma [1,2]. Since December 1999,
we have treated osteosarcoma with marginal resection
when a favorable response to chemotherapy is clinically
obtained. The purpose of this study was to evaluate the
long-term clinical outcomes of marginal resection for
osteosarcoma of the extremities.* Correspondence: yxch48@vip.sina.com
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Patient and chemotherapy protocol
Between December 1999 and October 2008, 50 patients
with osteosarcoma (28 male, 22 female; average age of
17 years) underwent marginal resection following effec-
tive preoperative chemotherapy. The distal femur was
involved in 24 patients, proximal tibia in 19, proximal
humerus in 4, proximal fibula in 2, and proximal femur
in 1. Of the 50 patients, 49 patients had stage IIB, and 1
had stage IIIB cancer. Chemotherapy drugs comprised
high-dose methotrexate (HD-MTX 10 g/m2), adriamycin
(ADR 90 mg/m2), ifosfamide (IFO 2.0 g/m2 × 5), and cis-
platin (DDP 120 mg/m2), given as one of two chemo-
therapy protocols: the MMIA protocol (HD-MTX, ADR
and IFO) and the DIA protocol (DDP, ADR and IFO). Of
the 50 patients, 32 received DIA and 18 received MMIA.
Before surgery, Since the 1980s, osteosarcoma has com-
monly been treated with neoadjuvant chemotherapy. 6 to
10 courses of chemotherapy were performed.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The effectiveness of chemotherapy was evaluated before
surgery by clinical evidence, laboratory tests, plain radiog-
raphy and magnetic resonance imaging (MRI). Evidence
of a good chemotherapeutic response included alleviation
of pain, shrinkage and hardening of the local mass, im-
proved range of motion in the affected limb; reduction
in serum alkaline phosphatase (ALP) and lactate dehy-
drogenase (LDH) concentrations; sclerotic changes and
clearly defined lesion margins observed on plain radio-
graphs; and marked shrinkage of the tumor, reduction in
marrow edema, and shrinkage of tumor extension into
soft tissue observed on MRI.
The grade of tumor cell necrosis rate (TCNR) was
classified according to the Huvos necrosis grading sys-
tem [3]: grade I, necrosis rarely seen; grade II, <50%
and ≤90% tumor necrosis; grade III, >90% and <100%
necrosis; and grade IV, 100% necrosis. Grades I and II
were defined as poor responses, and grades III and IV as
good responses (Figure 1).
Surgical procedure
Limb-salvaging surgery was conducted by means of
intentional marginal resection, defined as the plane of dis-
section through the pseudocapsule or peritumoral reactiveFigure 1 Osteosarcoma arising from the left distal femur in a 15-year
(MRI) scan of the tumor obtained before neoadjuvant chemotherapy; arrows
(H&E), original magnification × 40). (C,D) After chemotherapy. (C) MRI scan of
extension into the epiphysis. Extensive calcification and the significantly reduc
indicated a good response to therapy. (D) Significant tumor cell degenerationtissue. This technique preserves important structures such
as the major neurovascular bundles, tendons, ligaments,
muscles, and the epiphysis. Of the 50 patients, 28 under-
went tumor resection and implantation of autoclaved
bone graft. For these patients, the possibility for preserva-
tion of the epiphysis was compatible with the MRI fin-
dings. The epiphysis was preserved in six (Figure 2).
Of the remaining 22 patients, 17 underwent tumor re-
section and prosthetic replacement, 3 underwent tumor
resection with autograft implantation, and 2 patients
with involvement of the proximal fibula underwent mar-
ginal tumor resection of the fibula head, preserving the
common peroneal nerve, lateral collateral ligament, and
biceps femoris tendon.
Observation and follow-up
After completion of chemotherapy, patients were exam-
ined by radiography of the operated limb and computed
tomography of the chest every 3 months for 2 years,
then at at 6-month intervals for another 3 years. Re-
currence, metastasis, and death were recorded. The
functions of the affected limb were evaluated using the
revised 30-point functional classification system estab-
lished by the International Society of Limb Salvage and
the Musculoskeletal Tumor Society (MSTS93) [4].-old boy. (A,B) Before chemotherapy. (A) Magnetic resonance imaging
show lesions in longest diameter. (B) Tumor cells (hematoxylin and eosin
the same tumor after chemotherapy showed that there was no tumor
ed lesion (arrows, the sum of the longest diameter ≥30% reduction)
and necrosis (H&E, original magnification × 40).
Figure 2 Results for a patient treated for osteosarcoma. (A) The epiphysis of the distal femur was preserved by marginal resection; (B) the
remaining epiphysis; and (C) the resected tumor. (D) The radiograph shows that after an intramedullary nail and screws had been inserted into
the residual epiphysis and the bone defect filled with bone cement (no barium), the implanted bone healed successfully.
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The Kaplan-Meier method was used for survival ana-
lysis. All statistics were performed with SPSS software




All 50 patients completed preoperative chemotherapy. The
histological response to preoperative chemotherapy was
grade IV in 27 patients, grade III in 16, and grade II in 7.
All patients also underwent postoperative chemotherapy.
Of the 50 patients, 19 were unable to complete planned
chemotherapy; 16 of these were due to early progression,
and 3 because of lack of funds. Of the remaining 31 pa-
tients, 26 received all 12 cycles of chemotherapy, 3 received
11 cycles, and 2 received 10 cycles. A total of 455 cycles of
chemotherapy were carried out for the 50 patients.
Complications
During follow-up, four patients underwent reoperation.
One patient underwent open reduction, bone grafting,and internal fixation because of an inactivated bone frac-
ture at 26 months after the initial surgery; the bone had
healed well by 4 months after reoperation. At 100 months
after the second operation, the patient was able to walk
without orthopedic footwear, but the affected limb was
2 cm shorter than the unaffected limb. Flexion of the
affected knee joint was 110° with a limb function score
of 28.
The second patient required reoperation 18 months
after the first operation because of inactivated bone frac-
ture. At 42 months after the first operation, this patient
was able to walk normally. The affected limb was 1 cm
shorter than the unaffected limb and flexion of the
affected knee joint was 135°, with a limb function score
of 30.
The thrid patient underwent open reduction and allo-
grafting combined with autografting for inactivated bone
fracture 12 months after the initial surgery.
The fourth patient underwent arthroscopic release,
quadricepsplasty, and continuous passive motion for
knee stiffness at 3 years after the initial operation. At the
last follow-up, 89 months after the initial operation, the
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normal flexion.
Survival analysis
Living patients were followed clinically for a minimum
of 5 years. The median follow-up was 5.5 years (range 8
to 160 months) for all patients, and 7.3 years (range, 60
to 160 months) for living patients. Three patients were
lost to follow-up.
Four patients had local recurrence (time lapse ranged
from 6 to 21 months after surgery) and two of them
underwent amputation; the local recurrence rate for this
group was 8.5% (4/47). Pulmonary metastases developed
in 20 patients (42.6%) during follow-up; 19 died and 1 is
currently alive with tumor.
For the full patient group, the overall 5-year survival
rate was 61.7%, and the event-free survival rate was
57.7% (Figure 3).
Functions
Functional evaluation of these patients was classified ac-
cording to MSTS criteria: limb function was excellent in
24 patients, good in 12, fair in 10 and poor in 4. The
combined excellent and good rate for affected limbs was
72%. Of the six patients who underwent limb-salvage
operations that preserved the epiphysis, three could flexFigure 3 Overall survival and event-free survival of patients with ostethe affected knee joint to 110°, two could flex 90° to
110°, and one could flex 60° to 90°. The length of the
affected limb equaled that of the unaffected limb in four
patients, and was 2 cm shorter than the other limb in
two patients.
Discussion
The current standard treatment for osteosarcoma in-
cludes neoadjuvant chemotherapy and limb-sparing sur-
gery. Currently, two methods of tumor resection exist:
wide resection and marginal resection. This surgical sta-
ging system proposed by Enneking et al. [5] incorporates
margin definitions predicting for local recurrence based
on the relationship of the surgical margin to the neo-
plasm and its surrounding pseudocapsule and reactive
zone. Wide resection is defined as removal of the gross
tumor with at least 3 cm of normal surrounding soft tis-
sue and 5 cm of normal surrounding bone tissue. Wide
resection often requires excising more normal soft and
bone tissue around the osteosarcoma, leading to a higher
rate of operative complications and poorer limb function.
Marginal resection, defined as plane of dissection through
the pseudocapsule or peritumoral reactive tissue, removes
the gross tumor with 1 cm of normal surrounding soft
tissue and 2 to 3 cm of normal surrounding bone tissue.
Marginal resection can preserve the surrounding areasosarcoma treated in our hospital.
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blood vessels, and the epiphysis region. Marginal resection
of osteosarcoma should be performed only if the pre-
operative chemotherapeutic effect has been rated as a
good response.
The aims of marginal resection of osteosarcoma are to
reduce bone and soft-tissue defects and to improve limb
function, without increasing the risk of local recurrence
or jeopardizing the patient’s life. Since 1987 to 2004,
Tsuchiya’s group have treated 21 patients with osteosar-
coma with intentional marginal resection following good
results from chemotherapy [1,2,6]. Four patients with
lesions in the proximal fibula were treated by marginal
resection of the fibular head, which preserved the com-
mon peroneal nerve, lateral collateral ligament, and bi-
ceps femoris tendon. The epiphysis was preserved in
eight patients, and the bone defect was reconstructed by
distraction osteogenesis. Joint resection (resection of one
or both epiphyses) was performed in nine patients. No
local tumor recurrence was seen during a mean follow-
up of 97 months. Pulmonary metastases developed in
four patients during a a mean follow-up of 35.8 months.
The overall cumulative survival rate was 100% and the
event-free survival rate was 78%. The overall average
function of the 21 patients was evaluated as 93% of nor-
mal. Thus, this group considered that it was possible to
treat osteosarcoma by marginal resection along with
good preoperative chemotherapy.
Between December 1999 and October 2008, we treated
osteosarcoma with marginal resection [7], when a favor-
able response to chemotherapy was clinically obtained.
During this period, 50 patients underwent marginal resec-
tion and were followed up for a mean time of 5.5 years.
Four patients had a local recurrence with time lapse ran-
ging from 6 to 21 months after surgery (local recurrence
rate 8.5%). Pulmonary metastases developed in 20 patients
(42.6%) during follow-up. The overall 5-year survival rate
was 61.7%, and the event-free survival rate was 57.7%. We
consider that marginal resection is an option for oste-
osarcoma with good response to preoperative chemo-
therapy, because our data are similar to those reported by
others [8-12].
Effect of chemotherapy and size of surgical margin are
the most important factors for osteosarcoma prognosis,
and Tsuchiya et al. suggested that the former is more
important than the latter for limb-salvaging procedures
[1]. Efficient chemotherapy improves prognosis and min-
imizes surgical margins. Thus, when a smaller resection
margin is being considered, it is most important to con-
firm the effectiveness of chemotherapy and the accuracy
of preoperative assessment of the extent of intramedul-
lary tumor. When a good response is documented by at
least two of four radiological methods, including plain
radiography, MRI, angiography, and 201Ti scintigraphy,more than 90% tumor necrosis can be expected and
minimized resection can be performed [6]. We con-
firmed preoperative chemotherapeutic effects not only
by plain radiography and MRI but also by changes in
clinical appearance and serum LDH and ALP concentra-
tions [13]. We considered that the following provided
evidence of good chemotherapeutic response: reduction
of pain; shrinkage and rigidity of any local mass; normal
range of movement of the affected limb; reduction of
serum ALP and LDH to within the normal range; scle-
rotic changes and clearly defined lesion margins visible
on plain radiographs; and marked shrinkage of tumor,
reduction of marrow edema, and marked shrinkage of
any extension of the tumor into soft tissue on MRI. If
these did not occur, the chemotherapeutic response was
graded as poor.
Conclusions
Our results showed that marginal resection should be
performed by an experienced surgeon who is familiar
with handling limb salvage in cases of malignant bone
tumor. In conclusion, no adverse effects on survival or
local recurrence were found, and our outcomes indicate
that it is possible to perform marginal limb-sparing sur-
gery in conjunction with effective chemotherapy for limb
osteosarcoma.
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